A Phase 3 Open-label Study Evaluating the Long-term Safety and Efficacy of Elexacaftor/Tezacaftor/Ivacaftor Triple Combination Therapy in Cystic Fibrosis Subjects 2 Years and Older
Latest Information Update: 02 May 2024
At a glance
- Drugs Elexacaftor/ivacaftor/tezacaftor (Primary) ; Ivacaftor (Primary)
- Indications Cystic fibrosis
- Focus Adverse reactions
- Sponsors Vertex Pharmaceuticals
- 25 Apr 2024 Status changed from recruiting to active, no longer recruiting.
- 23 Feb 2022 Time frame for primary outcome measure extended to 196 weeks.
- 23 Feb 2022 Planned End Date changed from 1 Mar 2024 to 1 Apr 2026.